Summary:
Phase 2/3, Randomized, Double-blind, Parallel group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder
Subjects who have successfully completed the washout of prior medication and have met the eligibility criteria, will be randomly assigned via a Randomization and Trial Supply Management (RTSM) system in a 1:1 ratio to one of two treatment arms: SEP-363856 (50 - 75 mg/day) or placebo. Dosing of study drug will begin the evening of the Baseline Visit. Treatment will continue once-daily, in the evening at bedtime, for the remainder of the 8-week Treatment Period.
Qualified Participants May Receive:
Qualified participants will be paid for each completed visit.